Treace Medical closes public offering of 5.48M shares, net proceeds ~$107.5M

TREACE MEDICAL CONCEPTS, INC.

Offering of 5,476,190 shares (including full overallotment) at $21.00/share to the public.
Net proceeds of $107.5M after underwriting discounts and estimated offering expenses.
Underwriters purchased shares at $19.74/share; 90-day lock-up for insiders.
Underwritten by J.P. Morgan and Morgan Stanley; shelf registration on Form S-3 used.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

TREACE MEDICAL CONCEPTS, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC valued at Issuance and sale of 4,761,905 shares of common stock at $21.00 per share to public, underwriters pu (effective 2023-02-07).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC
Value: Issuance and sale of 4,761,905 shares of common stock at $21.00 per share to public, underwriters pu
Effective: 2023-02-07

Exact text from the filing

On February 7, 2023, Treace Medical Concepts, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 4,761,905 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (“Common Stock”), to the Underwriters (the “Offering”).

View on SEC.gov

Browse all material agreements →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-032511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.